Quantitative analysis of estrogen receptor heterogeneity in breast cancer

Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci USA, 98, 10869, 10.1073/pnas.191367098 Giltnane, 2004, Technology insight: identification of biomarkers with tissue microarray technology, Nat Clin Pract Oncol, 1, 104, 10.1038/ncponc0046 Kononen, 1998, Tissue microarrays for high-throughput molecular profiling of tumor specimens, Nat Med, 4, 844, 10.1038/nm0798-844 Anderson, 1998, Estrogen responsiveness and control of normal human breast proliferation, J Mammary Gland Biol Neoplasia, 3, 23, 10.1023/A:1018718117113 Sommer, 2001, Estrogen receptor and breast cancer, Semin Cancer Biol, 11, 339, 10.1006/scbi.2001.0389 Fisher, 1988, Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06, J Clin Oncol, 6, 1076, 10.1200/JCO.1988.6.7.1076 Early Breast Cancer Trialists' Collaborative Group, 1998, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4 Layfield, 1998, Tissue heterogeneity of immunohistochemically detected estrogen receptor. Implications for image analysis quantification, Am J Clin Pathol, 110, 758, 10.1093/ajcp/110.6.758 Camp, 2002, Automated subcellular localization and quantification of protein expression in tissue microarrays, Nat Med, 8, 1323, 10.1038/nm791 McCabe, 2005, Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis, J Natl Cancer Inst, 97, 1808, 10.1093/jnci/dji427 Camp, 2003, Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome, Cancer Res, 63, 1445 Chung, 2006, Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray, Cancer, 106, 1677, 10.1002/cncr.21783 Psyrri, 2005, Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis, Clin Cancer Res, 11, 5856, 10.1158/1078-0432.CCR-05-0420 Camp, 2004, X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization, Clin Cancer Res, 10, 7252, 10.1158/1078-0432.CCR-04-0713 Leong, 2001, Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems, Am J Clin Pathol, 115, 709, 10.1309/WBU9-22QN-C3NA-2Q12 Douglas-Jones, 2001, Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma, J Clin Pathol, 54, 951, 10.1136/jcp.54.12.951 Ono, 1996, Cancer cell morphology at the invasive front and expression of cell adhesion-related carbohydrate in the primary lesion of patients with colorectal carcinoma with liver metastasis, Cancer, 78, 1179, 10.1002/(SICI)1097-0142(19960915)78:6<1179::AID-CNCR3>3.0.CO;2-5 Kauppila, 1998, Aberrant type I and type III collagen gene expression in human breast cancer in vivo, J Pathol, 186, 262, 10.1002/(SICI)1096-9896(1998110)186:3<262::AID-PATH191>3.0.CO;2-3 Allred, 1990, Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance, Arch Surg, 125, 107, 10.1001/archsurg.1990.01410130113018 Mann, 2005, Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer, J Clin Oncol, 23, 5148, 10.1200/JCO.2005.02.076 Spataro, 1992, Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group), Ann Oncol, 3, 733, 10.1093/oxfordjournals.annonc.a058330 Davis, 1984, Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor, Eur J Cancer Clin Oncol, 20, 375, 10.1016/0277-5379(84)90084-1 Lluch, 1987, Intratumoral variations in cytoplasmic estrogen receptor levels in breast cancer, Breast Cancer Res Treat, 9, 69, 10.1007/BF01806696 Silfversward, 1980, Intratumoral variation of cytoplasmic and nuclear estrogen receptor concentrations in human mammary carcinoma, Eur J Cancer, 16, 59, 10.1016/0014-2964(80)90108-5 Ellis, 2001, Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial, J Clin Oncol, 19, 3808, 10.1200/JCO.2001.19.18.3808